Merck & Co., Inc. (NYSE:MRK) Shares Purchased by MainStreet Investment Advisors LLC

MainStreet Investment Advisors LLC lifted its holdings in Merck & Co., Inc. (NYSE:MRK) by 79.2% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 26,708 shares of the company’s stock after acquiring an additional 11,807 shares during the quarter. MainStreet Investment Advisors LLC’s holdings in Merck & Co., Inc. were worth $2,055,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Sowa Financial Group Inc. acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter worth $27,000. Total Clarity Wealth Management Inc. acquired a new stake in shares of Merck & Co., Inc. in the fourth quarter worth $27,000. Stephenson National Bank & Trust acquired a new stake in Merck & Co., Inc. during the fourth quarter valued at $28,000. Pacifica Partners Inc. acquired a new stake in Merck & Co., Inc. during the fourth quarter valued at $35,000. Finally, Lion Street Advisors LLC acquired a new stake in Merck & Co., Inc. during the first quarter valued at $35,000. Hedge funds and other institutional investors own 75.25% of the company’s stock.

Shares of NYSE:MRK traded down $0.26 during midday trading on Friday, hitting $76.29. The company’s stock had a trading volume of 4,285,188 shares, compared to its average volume of 10,489,316. The business’s 50 day simple moving average is $79.52 and its 200 day simple moving average is $83.41. The company has a debt-to-equity ratio of 0.82, a quick ratio of 0.87 and a current ratio of 1.11. The company has a market cap of $194.08 billion, a P/E ratio of 19.38, a price-to-earnings-growth ratio of 2.13 and a beta of 0.50. Merck & Co., Inc. has a 12-month low of $65.25 and a 12-month high of $92.64.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, April 28th. The company reported $1.50 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.34 by $0.16. The firm had revenue of $12.06 billion for the quarter, compared to the consensus estimate of $11.46 billion. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 52.46%. The company’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same period last year, the firm posted $1.22 earnings per share. On average, sell-side analysts predict that Merck & Co., Inc. will post 5.31 earnings per share for the current fiscal year.

Several analysts recently commented on the stock. SVB Leerink dropped their price target on shares of Merck & Co., Inc. from $98.00 to $95.00 and set an “outperform” rating on the stock in a research report on Wednesday, April 29th. Barclays dropped their price target on shares of Merck & Co., Inc. from $93.00 to $90.00 and set an “overweight” rating on the stock in a research report on Wednesday, April 29th. Morgan Stanley dropped their price target on shares of Merck & Co., Inc. from $97.00 to $89.00 and set an “overweight” rating on the stock in a research report on Thursday, April 2nd. ValuEngine upgraded shares of Merck & Co., Inc. from a “sell” rating to a “hold” rating in a research report on Saturday, February 29th. Finally, UBS Group dropped their price target on shares of Merck & Co., Inc. from $96.00 to $92.00 and set a “buy” rating on the stock in a research report on Monday, April 13th. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $93.60.

In other news, Director Wendell P. Weeks sold 5,000 shares of the firm’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $76.02, for a total value of $380,100.00. Following the transaction, the director now directly owns 5,100 shares of the company’s stock, valued at $387,702. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.28% of the company’s stock.

About Merck & Co., Inc.

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Story: Blue-Chip Stocks

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.